on semaglutide First Week GLP-1: How Your Body May Respond Penn study focuses on semaglutide

Semaglutide for weight management (Wegovy) is FDA-approved only for adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia

You start out at 0.25-milligram once a week for 4 weeks

Pre-existing gallbladder disease represents a significant consideration

Ali's clinical foundation in emergency medicine means she approaches metabolic health with the same rigor she applies to every aspect of patient care, clear expectations, honest assessment of what GLP-1 therapy can and cannot do, and ongoing oversight from start to finish